The US Food and Drug Administration granted a traditional Chinese medicine used to treat cancer approval to enter the third phase of clinical trials in the United States. Known as Kanglaite Injection, the drug was developed by Zhejiang Chinese Medical University and contains extracts from the seed of coix, a grasslike relative of maize. It has been used as a cancer treatment in China since 1995 and is the first TCM injection treatment to undergo the FDA approval process.

(Source: China Daily)